课题基金 / 基金详情

Thrombostatin In The Folts Model for Coronary Thrombosis

Thrombostatin In The Folts Model for Coronary Thrombosis
Folts 冠状动脉血栓模型中的凝血酶抑制素
批准号:
6338041
负责人:
ALVIN H SCHMAIER
金额:
$58.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-05-15 至 2004-03-31

项目摘要

项目成果

ALVIN H SCHMAIER的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人的逐字描述):本提案的假设 是一种选择性干扰血小板的凝血酶抑制物 激活将是治疗急性脑出血的重要治疗手段 冠脉综合征。Thromgen,Inc.正在开发一种称为 血栓抑素作为抗凝血酶、抗血小板药物用于心脏 攻击和介入性心血管手术。凝血酶抑制素预防 A-凝血酶激活血小板。它是一种双功能抑制剂, 与凝血酶S活性部位的相互作用弱,与凝血酶的相互作用更紧密 凝血酶受体,蛋白酶激活受体1(PAR 1)。凝血酶抑素是一种 新型血小板选择性凝血酶抑制剂。这项建议的具体目的 详情如下: 具体目标1:将进行研究,以制备更有效和更有选择性的 经验法合成凝血酶活性抑制物PAR1及其合理应用 药物设计。 特定目标2:血栓抑素和血小板的抗血栓形成能力 糖蛋白IIb/IIIa拮抗剂将在狗身上进行比较。 这些研究将导致开发出一类新的 用于预防动脉血栓形成的血小板选择性凝血酶抑制剂。这些 调查还将导致一种新的治疗方法来管理 急性冠脉综合征的患者。 建议的商业应用: 不可用
英文摘要
DESCRIPTION (Applicant's Description Verbatim): The hypothesis of this proposal is that a thrombin inhibitor that selectively interferes with platelet activation will be an important therapeutic agent in the management of acute coronary syndromes. Thromgen, Inc. is developing a class of agents called thrombostatin as antithrombin, anti-platelet drugs to be used for heart attacks and interventional cardiovascular procedures. Thrombostatin prevents a-thrombin from activating platelets. It is a bifunctional inhibitor that weakly interacts with thrombin' s active site and more tightly interacts with thrombin's receptor, protease-activated receptor 1 (PAR 1). Thrombostatin is a novel platelet-selective thrombin inhibitor. The specific aims of this proposal are as follows: Specific Aim #1: Studies will be done to prepare more potent and selective inhibitors of thrombin activation of PAR1 by empiric synthesis and rational drug design. Specific Aim #2: The antithrombotic ability of thrombostatin and platelet glycoprotein IIb/IIIa antagonists will be compared in dogs. These investigations will result in the development of a novel class of platelet-selective thrombin inhibitors to prevent arterial thrombosis. These investigations also will result in a new therapeutic approach to the management of patients with acute coronary syndromes. PROPOSED COMMERCIAL APPLICATION: Not Available
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tyrosine Kinases and Thrombosis
  • 批准号:
    10367450
  • 项目类别:
  • 资助金额:
    $54.01万
  • 财政年份:
    2022
  • 负责人:
    ALVIN H SCHMAIER
  • 依托单位:
Tyrosine Kinases and Thrombosis
  • 批准号:
    10573189
  • 项目类别:
  • 资助金额:
    $46.78万
  • 财政年份:
    2022
  • 负责人:
    ALVIN H SCHMAIER
  • 依托单位:
KININ2018CLE
  • 批准号:
    9471651
  • 项目类别:
  • 资助金额:
    $1.25万
  • 财政年份:
    2018
  • 负责人:
    ALVIN H SCHMAIER
  • 依托单位:
Prolylcarboxypeptidase is a Risk Factor for Cardiovascular Disease
  • 批准号:
    8262208
  • 项目类别:
  • 资助金额:
    $11.78万
  • 财政年份:
    2012
  • 负责人:
    ALVIN H SCHMAIER
  • 依托单位:
海外基金